Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Editas Medicine stock price, quote, forecast and news

EDIT
US28106W1036
A2AC4K

Price

5.65
Today +/-
+0
Today %
+0 %
P

Editas Medicine Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Editas Medicine, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Editas Medicine from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Editas Medicine’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Editas Medicine. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Editas Medicine’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Editas Medicine’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Editas Medicine’s growth potential.

Editas Medicine Revenue, EBIT and net profit per share

DateEditas Medicine RevenueEditas Medicine EBITEditas Medicine Net Income
2030e1.1 B undefined98.06 M undefined-838,848 undefined
2029e497.77 M undefined38.11 M undefined-73.26 M undefined
2028e289.5 M undefined-113.81 M undefined-86.61 M undefined
2027e173.36 M undefined-201.06 M undefined-170.08 M undefined
2026e66.56 M undefined-283.15 M undefined-222.62 M undefined
2025e23.92 M undefined-265.19 M undefined-220.11 M undefined
2024e32.81 M undefined-240.69 M undefined-226.46 M undefined
202378.12 M undefined-169.18 M undefined-153.22 M undefined
202219.71 M undefined-225.95 M undefined-220.43 M undefined
202125.54 M undefined-193.15 M undefined-192.5 M undefined
202090.73 M undefined-134.84 M undefined-115.98 M undefined
201920.53 M undefined-140.92 M undefined-133.75 M undefined
201831.94 M undefined-113.73 M undefined-109.95 M undefined
201713.73 M undefined-119.93 M undefined-120.32 M undefined
20166.05 M undefined-97.19 M undefined-97.23 M undefined
20151.63 M undefined-35.31 M undefined-73.29 M undefined
20140 undefined-12.72 M undefined-13.99 M undefined
20130 undefined-1.74 M undefined-1.78 M undefined

Editas Medicine Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000.010.010.030.020.090.030.020.080.030.020.070.170.290.51.1
---500.00116.67138.46-35.48350.00-72.22-24.00310.53-58.97-28.13186.96162.1267.0571.97121.93
------------------
000000000000000000
-1-12-35-97-119-113-140-134-193-225-169-240-265-283-201-1133898
---3,500.00-1,616.67-915.38-364.52-700.00-148.89-772.00-1,184.21-216.67-750.00-1,152.17-428.79-116.18-39.107.658.88
-1-13-73-97-120-109-133-115-192-220-153-226-220-222-170-86-730
-1,200.00461.5432.8823.71-9.1722.02-13.5366.9614.58-30.4547.71-2.650.91-23.42-49.41-15.12-
35.735.735.732.2240.3247.149.9858.6167.6268.6675.970000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Editas Medicine Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Editas Medicine is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Editas Medicine provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Editas Medicine's financial health and stability.

Assets

Editas Medicine's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Editas Medicine must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Editas Medicine after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Editas Medicine's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-1-13-72-97-120-109-133-115-192-220-153
00012323566
00000000000
022617702665-102-218-1
01444460605157885736
00000000000
00000000000
0-8-5-50-9-45-40-179-163-177-132
0-1-1-3-2-4-6-7-7-4-4
0-1-1-3-183-5312-140-54114-3
0000-181-4818-133-461180
00000000000
0000-1000000
21814197155871312242821118
21813997154861312242821118
---1.00--------
00000000000
2813243-38-11103-9663-62-17
-0.98-9.88-6.87-53.74-11.48-50.46-46.84-187-171.78-181.47-136.9
00000000000

Editas Medicine stock margins

The Editas Medicine margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Editas Medicine. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Editas Medicine.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Editas Medicine's sales revenue. A higher gross margin percentage indicates that the Editas Medicine retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Editas Medicine's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Editas Medicine's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Editas Medicine's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Editas Medicine. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Editas Medicine's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Editas Medicine Margin History

Editas Medicine Gross marginEditas Medicine Profit marginEditas Medicine EBIT marginEditas Medicine Profit margin
2030e0 %8.89 %-0.08 %
2029e0 %7.66 %-14.72 %
2028e0 %-39.31 %-29.92 %
2027e0 %-115.98 %-98.11 %
2026e0 %-425.39 %-334.45 %
2025e0 %-1,108.48 %-920.03 %
2024e0 %-733.58 %-690.22 %
20230 %-216.56 %-196.13 %
20220 %-1,146.37 %-1,118.37 %
20210 %-756.26 %-753.72 %
20200 %-148.62 %-127.83 %
20190 %-686.41 %-651.49 %
20180 %-356.07 %-344.24 %
20170 %-873.49 %-876.33 %
20160 %-1,606.45 %-1,607.11 %
20150 %-2,166.26 %-4,496.32 %
20140 %0 %0 %
20130 %0 %0 %

Editas Medicine Stock Sales Revenue, EBIT, Earnings per Share

The Editas Medicine earnings per share therefore indicates how much revenue Editas Medicine has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Editas Medicine earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Editas Medicine's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Editas Medicine’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Editas Medicine's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Editas Medicine Revenue, EBIT and net profit per share

DateEditas Medicine Sales per ShareEditas Medicine EBIT per shareEditas Medicine Earnings per Share
2030e13.41 undefined0 undefined-0.01 undefined
2029e6.05 undefined0 undefined-0.89 undefined
2028e3.52 undefined0 undefined-1.05 undefined
2027e2.11 undefined0 undefined-2.07 undefined
2026e0.81 undefined0 undefined-2.71 undefined
2025e0.29 undefined0 undefined-2.68 undefined
2024e0.4 undefined0 undefined-2.75 undefined
20231.03 undefined-2.23 undefined-2.02 undefined
20220.29 undefined-3.29 undefined-3.21 undefined
20210.38 undefined-2.86 undefined-2.85 undefined
20201.55 undefined-2.3 undefined-1.98 undefined
20190.41 undefined-2.82 undefined-2.68 undefined
20180.68 undefined-2.41 undefined-2.33 undefined
20170.34 undefined-2.97 undefined-2.98 undefined
20160.19 undefined-3.02 undefined-3.02 undefined
20150.05 undefined-0.99 undefined-2.05 undefined
20140 undefined-0.36 undefined-0.39 undefined
20130 undefined-0.05 undefined-0.05 undefined

Editas Medicine business model

Editas Medicine Inc. is a rising biopharmaceutical company specializing in the development of groundbreaking therapies based on genome editing. Its goal is to combat genetic diseases and other genetically related disorders by selectively modifying DNA sequences. The company was founded in 2013 by a group of renowned scientists, including prominent genome editors Jennifer Doudna and George Church. Over the years, Editas Medicine Inc. has established itself as a pioneer in the field of genome editing and has received numerous awards and funding. Its business model revolves around researching and developing innovative therapies based on genetic modifications, using approaches such as CRISPR/Cas9, TALEN, and zinc finger nucleases. The company aims to develop treatments for previously incurable, severe diseases. Its activities are divided into various business areas, including the exploration of gene therapies, the development of medications based on CRISPR/Cas9 technology, and the research of genome-based diagnostic options. Editas Medicine Inc. has already introduced some products to the market or is in advanced stages of development, such as the medication LCA10 for a rare form of blindness and the medication CEP290 for a severe genetic disease. Overall, Editas Medicine Inc. has experienced remarkable growth in recent years, becoming one of the key players in genome editing. The market for gene therapies and genome-based treatments has significant growth potential, making the company's prospects promising. Editas Medicine Inc. is dedicated to advancing genomic medicine by developing groundbreaking solutions for incurable diseases and providing a platform for new technologies in the market. Editas Medicine is one of the most popular companies on Eulerpool.com.

Editas Medicine SWOT Analysis

Strengths

Editas Medicine Inc is equipped with advanced gene editing technology, which allows them to develop innovative therapies and solutions for genetic diseases. This technology provides them with a competitive edge in the market.

Editas Medicine Inc has a robust intellectual property portfolio, consisting of patents and licenses related to gene editing technology. This protects their inventions and provides a legal barrier for potential competitors.

Editas Medicine Inc has established strategic partnerships with renowned pharmaceutical companies and academic institutions. These partnerships facilitate collaborative research, access to resources, and potential market expansion opportunities.

Weaknesses

Editas Medicine Inc currently has a limited product pipeline, which could pose a challenge in terms of revenue generation and growth. They need to actively focus on expanding their portfolio to diversify their offerings.

Editas Medicine Inc's success is dependent on obtaining regulatory approvals for their gene therapies. Delays or rejections in the approval process could significantly impact their ability to bring products to market and generate revenue.

Opportunities

The demand for gene therapies is on the rise, presenting Editas Medicine Inc with an opportunity to address unmet medical needs and capitalize on a growing market. They can leverage their technology to develop effective treatments for various genetic disorders.

Editas Medicine Inc can explore opportunities in emerging markets, where access to advanced medical treatments might be limited. By expanding their presence in such markets, they can reach a wider patient population and increase their market share.

Threats

Editas Medicine Inc faces competition from established pharmaceutical companies that have their own gene editing technologies. This competitive landscape can pose challenges in terms of market share, pricing, and customer adoption.

The gene editing industry is subject to strict regulations and ethical considerations. Editas Medicine Inc needs to navigate these challenges and ensure their operations and products adhere to legal and ethical frameworks.

Editas Medicine historical P/E ratio, EBIT, and P/S ratio.

Editas Medicine shares outstanding

The number of shares was Editas Medicine in 2023 — This indicates how many shares 75.966 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Editas Medicine earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Editas Medicine's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Editas Medicine’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Editas Medicine's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Editas Medicine.

Editas Medicine latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.68 -0.76  (-12.09 %)2024 Q1
12/31/2023-0.55 -0.23  (58.41 %)2023 Q4
9/30/2023-0.58 -0.55  (5.09 %)2023 Q3
6/30/2023-0.78 -0.56  (28.07 %)2023 Q2
3/31/2023-0.8 -0.71  (11.22 %)2023 Q1
12/31/2022-0.82 -0.88  (-7.53 %)2022 Q4
9/30/2022-0.89 -0.81  (8.6 %)2022 Q3
6/30/2022-0.84 -0.78  (6.93 %)2022 Q2
3/31/2022-0.81 -0.74  (8.77 %)2022 Q1
12/31/2021-0.74 -0.61  (17.05 %)2021 Q4
1
2
3
4

Eulerpool ESG Scorecard© for the Editas Medicine stock

Eulerpool World ESG Rating (EESG©)

58/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

20

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees52
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Editas Medicine list of shareholders

%
Name
Stocks
Change
Date
7.95 % BlackRock Institutional Trust Company, N.A.6,538,583-14,51712/31/2023
6.66 % Deep Track Capital LP5,473,086-1,628,84912/31/2023
3.16 % Two Sigma Investments, LP2,598,894259,30612/31/2023
2.91 % Dimensional Fund Advisors, L.P.2,392,396690,36612/31/2023
2.41 % Pictet Asset Management Ltd.1,981,679181,57812/31/2023
2.31 % Geode Capital Management, L.L.C.1,901,73593,75612/31/2023
10.65 % State Street Global Advisors (US)8,760,1513,690,6083/31/2024
10.27 % The Vanguard Group, Inc.8,450,110-74,35112/31/2023
1.93 % Millennium Management LLC1,590,809426,03612/31/2023
1.44 % D. E. Shaw & Co., L.P.1,187,564518,81912/31/2023
1
2
3
4
5
...
10

Editas Medicine Executives and Management Board

Dr. Gilmore O Neill59
Editas Medicine President, Chief Executive Officer, Director (since 2022)
Compensation 9.06 M
Dr. Baisong Mei59
Editas Medicine Senior Vice President, Chief Medical Officer
Compensation 3.01 M
Dr. Bruce Eaton69
Editas Medicine Executive Vice President
Compensation 2.74 M
Dr. Jessica Hopfield58
Editas Medicine Lead Independent Director
Compensation 292,473
Ms. Emma Reeve
Editas Medicine Independent Chairman of the Board
Compensation 259,973
1
2
3
4

Editas Medicine Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Beam Therapeutics Stock
Beam Therapeutics
SupplierCustomer0,900,990,360,810,900,60
Catalent Stock
Catalent
SupplierCustomer0,640,850,910,950,700,39
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer0,270,580,06-0,79-0,31-0,21
Modalis Therapeutics Stock
Modalis Therapeutics
SupplierCustomer0,220,890,480,960,85-
Bayer Stock
Bayer
SupplierCustomer-0,030,600,16-0,68-0,61-0,33
MaxCyte Stock
MaxCyte
SupplierCustomer-0,430,020,460,93--
Verve Therapeutics Stock
Verve Therapeutics
SupplierCustomer-0,540,760,170,78--
1

Most common questions regarding Editas Medicine

What values and corporate philosophy does Editas Medicine represent?

Editas Medicine Inc is a leading biotechnology company specializing in genome editing. As a company, Editas Medicine Inc represents values of innovation, scientific advancement, and patient-centered focus. Their corporate philosophy revolves around the commitment to revolutionize medicine by harnessing the potential of CRISPR technology. By developing novel gene editing therapies, Editas Medicine Inc aims to address previously untreatable genetic diseases and make a positive impact on the lives of patients. The company's dedication to cutting-edge research and collaboration with other industry leaders underscores their mission to provide transformative solutions through precise genomic medicine.

In which countries and regions is Editas Medicine primarily present?

Editas Medicine Inc is primarily present in the United States.

What significant milestones has the company Editas Medicine achieved?

Editas Medicine Inc has achieved several significant milestones in its journey. Notably, the company successfully completed its initial public offering (IPO) in early 2016, raising substantial capital to support its research and development efforts. Additionally, Editas Medicine Inc became the first company to obtain a U.S. FDA Investigational New Drug (IND) clearance for a CRISPR gene-editing therapy called EDIT-101, aimed at treating a rare form of blindness. This achievement marked a groundbreaking advancement in the field of gene therapy. Furthermore, the company has formed strategic partnerships with leading healthcare organizations and pharmaceutical companies, further strengthening its position in the market. Overall, Editas Medicine Inc continues to pave the way for innovative advancements in gene editing and remains dedicated to transforming the future of medicine.

What is the history and background of the company Editas Medicine?

Editas Medicine Inc, founded in 2013, is a leading genome editing company that focuses on translating its CRISPR-based technology into novel therapeutics. The company aims to develop transformative genome editing solutions to treat a wide range of diseases on a genetic level. Editas Medicine has a strong research and development team that works tirelessly to advance its pipeline of potential therapies. With a vision to revolutionize medicine, Editas Medicine strives to bring innovative treatments to patients suffering from debilitating genetic disorders. The company's commitment to cutting-edge technology and groundbreaking research positions Editas Medicine as a pioneering force in the field of genome editing.

Who are the main competitors of Editas Medicine in the market?

The main competitors of Editas Medicine Inc in the market include other companies involved in gene editing and gene therapy research, such as Intellia Therapeutics Inc, CRISPR Therapeutics AG, and Sangamo Therapeutics Inc. These companies also focus on developing therapies aiming to treat genetic diseases and conditions using advanced gene editing technologies. While Editas Medicine Inc has been at the forefront of the gene editing industry, these competitors demonstrate significant potential and innovation in the field, contributing to a competitive landscape that fosters advancements in gene therapy.

In which industries is Editas Medicine primarily active?

Editas Medicine Inc is primarily active in the biotechnology industry.

What is the business model of Editas Medicine?

The business model of Editas Medicine Inc focuses on developing transformative genomic medicines. Editas Medicine is a leading clinical-stage biotechnology company, utilizing its proprietary CRISPR gene editing platform to discover, develop, and deliver innovative therapies to treat a wide range of serious diseases. With a strong emphasis on genetic medicines, Editas Medicine is dedicated to addressing genetic diseases at their source, aiming to provide potential cures or long-term solutions. By leveraging advanced CRISPR technology, Editas Medicine strives to provide life-changing therapies that have the potential to significantly improve patients' lives.

What is the P/E ratio of Editas Medicine 2024?

The Editas Medicine P/E ratio is -1.9.

What is the P/S ratio of Editas Medicine 2024?

The Editas Medicine P/S ratio is 13.08.

What is the AlleAktien quality score of Editas Medicine?

The AlleAktien quality score for Editas Medicine is 4/10.

What is the revenue of Editas Medicine 2024?

The expected Editas Medicine revenue is 32.81 M USD.

How high is the profit of Editas Medicine 2024?

The expected Editas Medicine profit is -226.46 M USD.

What is the business model of Editas Medicine

Editas Medicine Inc. is a biopharmaceutical company that focuses on developing therapies for the treatment of genetic diseases. The company utilizes advanced technologies, such as CRISPR/Cas9 genome editing, to develop targeted therapies that are intended to be more effective and safer than traditional treatment methods. Editas is divided into three business areas: ophthalmology, oncology, and rare diseases. In the field of ophthalmology, the company is working on the development of treatments for eye diseases such as Leber congenital amaurosis, an inherited retinal disease that can lead to blindness. The company is also working on treatments for other eye diseases such as retinitis pigmentosa and macular degeneration. Editas also has a portfolio of cancer therapies in the oncology field, including a treatment for blood cancer that targets the specific mutation of cancer cells. The company is also working on treatments for solid tumors, including lung and prostate cancer. In the field of rare diseases, Editas is working on the development of therapies for diseases that are often genetically determined and affect only a small number of patients. The company is focusing on the treatment of muscular dystrophies and hemophilia. To advance its business segments, Editas has established a number of partnerships and financing arrangements. Among its partners are some of the world's leading biopharmaceutical companies, as well as financing institutions that support the company in covering research and development costs. The company is also committed to making gene editing technology more accessible and safer. Editas has filed several patents on CRISPR/Cas9 technology and is working with regulatory authorities to ensure that gene editing is safe and effective. In line with the company's goals of making its technology accessible to the general public, Editas has released a portion of its technologies as open-source software to support researchers around the world in the development of therapies. Editas Medicine Inc. is an emerging force in the field of biopharmaceuticals with a focus on developing therapies for the treatment of genetic diseases. With its emphasis on safety, effectiveness, and transparency, the company has the potential to revolutionize the way we treat diseases.

What is the Editas Medicine dividend?

Editas Medicine pays a dividend of 0 USD distributed over payouts per year.

How often does Editas Medicine pay dividends?

The dividend cannot currently be calculated for Editas Medicine or the company does not pay out a dividend.

What is the Editas Medicine ISIN?

The ISIN of Editas Medicine is US28106W1036.

What is the Editas Medicine WKN?

The WKN of Editas Medicine is A2AC4K.

What is the Editas Medicine ticker?

The ticker of Editas Medicine is EDIT.

How much dividend does Editas Medicine pay?

Over the past 12 months, Editas Medicine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Editas Medicine is expected to pay a dividend of 0 USD.

What is the dividend yield of Editas Medicine?

The current dividend yield of Editas Medicine is .

When does Editas Medicine pay dividends?

Editas Medicine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Editas Medicine?

Editas Medicine paid dividends every year for the past 0 years.

What is the dividend of Editas Medicine?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Editas Medicine located?

Editas Medicine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Editas Medicine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Editas Medicine from 7/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/29/2024.

When did Editas Medicine pay the last dividend?

The last dividend was paid out on 7/29/2024.

What was the dividend of Editas Medicine in the year 2023?

In the year 2023, Editas Medicine distributed 0 USD as dividends.

In which currency does Editas Medicine pay out the dividend?

The dividends of Editas Medicine are distributed in USD.

All fundamentals about Editas Medicine

Our stock analysis for Editas Medicine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Editas Medicine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.